Asset Contribution Agreement under which we acquired assets and assumed liabilities from Pfizer, with Series A-1 Preferred Stock consideration, milestone payments and royalties
| Officer | Age | In this role | Joined | Source |
|---|---|---|---|---|
|
Zachary Roberts
Also a director
President and Chief Executive Officer
Title from the Form 8-K dated Jul 1, 2026
|
48 | Not stated | Not stated | |
|
David Chang, M.D., Ph.D.
Also a director
President and CEO
Title from the Form 4 dated Mar 16, 2026
|
66 | Not stated | Not stated | |
|
Ben Beneski
Senior Vice President and Chief Technical Officer
|
49 |
Since 2025
1 year
|
2019 | |
|
Earl Douglas
SVP, General Counsel
Title from the Form 4 dated Aug 21, 2026
|
63 | Not stated | Not stated |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
From the proxy statement filed Apr 30, 2026 · updated by the 8-K of May 28, 2026
| Director | Age | On board | Independent | Committees | Other public boards | Pay | Source |
|---|---|---|---|---|---|---|---|
|
Arie Belldegrun, M.D.
Board chair
|
76 |
2017
9 years
|
Not independent | None stated | None stated | Not stated | |
|
David Chang, M.D., Ph.D.
CEO
|
66 |
2018
8 years
|
Not independent | None stated | None stated | Paid as CEO | |
|
Franz Humer, Ph.D.
Lead independent director
|
79 |
2018
8 years
|
Independent |
Compensation Committee · Chair
|
None stated | Not stated | |
|
Deborah Messemer
|
68 |
2018
8 years
|
Independent |
Audit Committee · Chair
|
TPG Inc., PayPal Holdings, Inc. | Not stated | |
|
Vicki Sato, Ph.D.
|
77 |
2021
5 years
|
Independent |
Research and Development Committee
|
Vir Biotechnology, Inc. | Not stated | |
|
Owen Witte, M.D.
|
76 |
2018
8 years
|
Independent |
Nominating and Corporate Governance Committee · Chair
|
None stated | Not stated | |
|
Elizabeth Barrett
|
63 |
2021
5 years
|
Independent |
Audit Committee
Compensation Committee
|
Sage Therapeutics, Inc. | Not stated | |
|
John DeYoung
|
63 |
2018
8 years
|
Independent |
Compensation Committee
International and Business Development Oversight Committee
|
None stated | Not stated | |
|
Joshua Kazam
|
49 |
2017
9 years
|
Not independent | None stated | None stated | Not stated | |
|
Stephen Mayo, Ph.D.
|
64 |
2022
4 years
|
Independent |
Audit Committee
Research and Development Committee
|
Sarepta Therapeutics, Inc., Merck & Co., Inc. | Not stated | |
|
Zachary Roberts
Joined May 28, 2026
|
- | - | - | - | - | - | |
|
Todd Sisitsky
Leaving at the meeting
|
54 |
2018
8 years
|
Independent |
Nominating and Corporate Governance
|
None stated | Not stated |
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.
Asset Contribution Agreement under which we acquired assets and assumed liabilities from Pfizer, with Series A-1 Preferred Stock consideration, milestone payments and royalties
Sublease of office space in Los Angeles with rent payments made under the sublease
New sublease of 2,218 square feet of office space in Los Angeles, with base rent paid and tenant improvement contributions
Purchased 344,828 shares of common stock in the 2024 registered offering under the Securities Purchase Agreement at $2.90 per share
Purchased 344,828 shares of common stock in the 2024 registered offering under the Securities Purchase Agreement at $2.90 per share
Purchased 344,828 shares of common stock in the 2024 registered offering under the Securities Purchase Agreement at $2.90 per share
Acted as co-manager in the 2026 public offering and purchased 3,807,600 shares at $1.88 per share, with an aggregate underwriting discount
Loading...